The Cancerómica group of the University of Málaga is the only European team present in a new research work that, developed by 15 US centers, has identified synergistic drugs to regulate the metabolic reprogramming of cancer.
A step forward in research into this disease opens hopes for resistance to treatment for Gemcitabine, a classic drug for patients with pancreatic cancer.
“Cancer is a very complex disease that brings together many types and very diverse patients. Thus, pancreas is one of the worst prognosis, both because of the rapid progress and aggressiveness, and because of the difficulty of detection. It is the fourth that causes more deaths in men and women and, in particular, the type ‘Adenocarcinoma Ductal’, which is the one we studied, is the most abundant, explains the professor of the Department of Molecular Biology and Biochemistry of the UMA José Manuel Matés.
According to the researcher, the metabolic changes experienced by patients suffering from this condition are one of the genuine characteristics that cancer brings.
Therefore, metabolic blockade from target drugs is one of the most intense and best studied pathways in recent years.
Resistance to drugs
“We have detected that with the inhibition by ‘Gemcitabina’ the cancer continues reproducing using other parallel metabolic routes. Our goal has been to avoid resistance from other drugs such as ‘Digoxin’, which block the ‘HIF1-?’ (hypoxia inducible factor), and ‘Leflunomide’ protein, thus preventing the metabolic reprogramming of the tumor cells that cancel The effect of Gemcitabine, clarifies Matés.
Advancing towards the synergistic effect of different drugs to “annihilate” tumor growth, from studies of proteomics and metabolomics that show how vary the conditions of glucose and glutamine, essential these in all types of cancer, has been the contribution of this Group of UMA composed by a dozen researchers.
A multidisciplinary work of more than three years that has not gone unnoticed by the scientific journal ‘Cancer Cell’, the publication of research on cancer with the highest impact rate in its field that, in addition to the publication of an article, has dedicated A comment pondering its importance written by Professor Chi Dang of the Ludwig Cancer Research Institute in New York, an international benchmark in this field.
An ambitious research project that has involved more than 250 patients from clinical trials of different genetic profiles.
“Personalized oncology is the future. This will be the next step. Work individual responses to specific treatments using metabolic and drug synergy, “says the UMA professor.
15 research groups from the United States and one from the University of Málaga, as the only European representative, including Matés, Professors of Molecular Biology and Biochemistry Javier Márquez, Francisco Alonso and Juan Segura, but in which he also participated The Institute of Biomedical Research of Malaga (IBIMA) and the Laboratory of Proteomics of the Central Research Services (SCAI).
The American centers involved are: Boston Harvard Medical School, Weill Cornell Medical College of New York, University of Michigan, University of Colorado, University of Texas and the University of Nebraska.
Source :University of Málaga